AMMCS 2026 Plenary Speaker
Modelling Advancements in Bioheat Transfer
Dr. Manpreet Singh
[The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) in support of the Department of Defense Biotechnology High Performance Computing Software Applications Institute (BHSAI)]
In the realm of bioheat transfer, Dr. Singh's research on development of human physiology-based computationally predictive models of biological systems can assist in mitigating the risks associated with cold-related injuries (frostbite, hypothermia etc.) and increase Warfighter Readiness of soldiers in extreme cold-weather operations. Dr. Singh's anatomically detailed thermoregulatory model provides accurate thermal responses including temperature predictions of the body core temperature, mean skin temperature and as well as endurance times to cold injuries of the most susceptible body peripheral regions such as digits of hands and feet in the austere environmental conditions. Therefore, Dr. Singh’s research assisted in the development of militarily relevant medical products that provide early alerts of a rise and fall in core body temperature to help reduce the risk of thermal injury in the field and during training and deployment at US installations. Although the human thermoregulatory system maintains core body temperature at 37 °C, humans often fail to recognize early warning signs of an impending rise or fall in this temperature and hence fail to take appropriate mitigation strategies. Therefore, a temperature alerting system from Dr. Singh’s mathematical algorithms can be used during rest, exercise in the heat, cold and extreme cold environmental conditions (−40 °C) to inform the soldiers mitigate such injury risks. In this talk, Dr. Singh will also discuss key modifications to the Pennes bioheat equation, with particular emphasis on incorporating spatial heterogeneity in blood perfusion derived from medical imaging. Specifically, he integrates pixel-level blood perfusion data into the model, thereby relaxing the conventional assumption of uniform blood perfusion.
At the VII AMMCS International Conference, Dr. Manpreet Singh, currently, a Computational Research Scientist II with the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), supporting the Department of Defense Biotechnology High Performance Computing Software Applications Institute (BHSAI) is presenting his lecture as a winner of the AMMCS Kolmogorov-Wiener Prize 2023 for Young Researchers. The award was granted at the VI AMMCS meeting, organized jointly with the Canadian Applied and Industrial Mathematics Society. More details can be found here. Dr. Singh joined BHSAI in August 2022 and is currently investigating human physiology under extreme cold environments. His research provides nuanced understanding and targeted strategies to mitigate limb amputation risks due to frostbite, ensure occupational safety, guiding decisions on rewarming protocols and provide effective medical interventions across diverse sectors in the United States and more specifically, strategies for United States Army.
Award Citation
Dr. Manpreet Singh earned his Ph.D. with distinction in Mechanical Engineering from the Bioheat Transfer Laboratory at the University of Maryland, Baltimore County, in 2022. Dr. Singh is widely recognized for pioneering novel mathematical models in cancer research, particularly in breast and prostate oncology, as well as for his contributions to thermal physiology. His work has led to the development of a breakthrough multi-orifice, prolonged insulin delivery device for type 1 diabetes, which is currently being commercialized and undergoing human clinical trials in the United States and Europe. In addition, his open-source algorithms have been adopted by independent researchers for magnetic coil design and by medical device companies to address prosthetic joint infections through heat-based biofilm eradication using alternating magnetic fields. His research on magnetic nanoparticle-mediated hyperthermia is also being utilized by a European based company to develop treatments for glioblastoma, prostate, and lung tumors. Several of his past research projects are presently advancing through human clinical trials aimed at obtaining FDA 510(k) clearance and CE mark approval.